
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals is a profitable company with a diverse portfolio of biopharmaceutical assets and a commitment to sustainability. Their projected revenues from royalties, material sales, and collaborative agreements, coupled with a strong management team and unique investment approaches, make them a stable long-term investment option. With a recent increase in their stock price estimate to $340 per share, Ligand shows promising potential for continued growth through partnerships and acquisitions.
Bears say
Ligand Pharmaceuticals is facing several significant risks that can negatively impact the company's operations and financial performance. These risks include a heavy reliance on a limited number of revenue sources, potential slowdown or decline in sales of key commercial assets, and the company's dependency on its Captisol material. Additionally, Ligand's business model is highly reliant on partnerships and licensing agreements, which can be unpredictable and subject to delays or failures. The company also faces risks related to its drug development pipeline, which may experience setbacks or failures, impacting its potential for future revenue growth. Despite management's focus on sustainability, environmental and operational risks could also impact the company's financial performance. Overall, these risks indicate a negative outlook for Ligand Pharmaceuticals' stock.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares